Stock data
Fulcrum Therapeutics, Inc. (FULC)
Fulcrum Therapeutics, Inc. (FULC) reported net income of -US$74.88M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$84.77M | -US$74.88M | — |
| 2024 | — | — | -US$21.90M | -US$9.72M | — |
| 2023 | — | — | -US$110.66M | -US$97.33M | — |
| 2022 | — | — | -US$112.56M | -US$109.87M | — |
| 2021 | — | — | -US$81.05M | -US$80.85M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$26.18M | — |
| 2026-03-31 | — | -US$18.89M | — |
| 2025-12-31 | — | -US$20.33M | — |
| 2025-09-30 | — | -US$19.59M | — |
| 2025-06-30 | — | -US$17.30M | — |
| 2025-03-31 | — | -US$17.66M | — |
| 2024-12-31 | — | -US$16.57M | — |
| 2024-09-30 | — | -US$21.70M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.